



New Drugs September 2011 (Original New Drug Applications: FDA)

Generic Name	Trade Name	Indication(s)	CPG Action/Date
May 2011			
Factor XIII Concentrate (Human) Formulary Pg. 7	Corifact	<i>Hematological Agents: Antihemophilic Agents.</i> Indicated for routine prophylactic treatment of congenital factor XIII deficiency.	9/19/11 Physician Initiated/ Physician Consult
Hydroxyprogesterone Caproate Formulary Pg. 8	Makena	<i>Endocrine & Metabolic Agents: Sex Hormones: Progestins.</i> Indicated for reducing the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.	9/19/11 CTP holder may prescribe.
Azilsartan Medoxomil Formulary Pg. 13	Edarbi	<i>Cardiovascular Agents: Renin Angiotensin System Antagonists.</i> Indicated for the treatment of hypertension.	9/19/11 CTP holder may prescribe.
Roflumilast Formulary Pg. 14	Daliresp	<i>Respiratory Agents: Selective Phosphodiesterase 4.</i> Indicated for reducing the risk of COPD exacerbations in patients with severe COPD	9/19/11 CTP holder may prescribe.
Vilazodone Hydrochloride Formulary Pg. 17	Viibryd	<i>Central Nervous System Agents: Antidepressants: Selective Serotonin Reuptake Inhibitors.</i> Indicated for the treatment of major depressive disorder.	9/19/11 CTP holder may prescribe.
Belimumab	Benlysta	<i>Biologic/Immunologic Agents: Monoclonal Antibody.</i> Indicated for the	9/19/11 Physician Initiated/ Physician Consult

		treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus.	
Formulary Pg. 23			
Ioflupane I 123	DaTscan	<i>Diagnostic Aids: In Vivo Diagnostic Aids.</i> Indicated for SPECT brain imaging to assist in the evaluation of patients with suspected Parkinsonian syndrome.	9/19/11 When an APN is ordering a diagnostic test within their scope, the technician carrying out the test does so per protocol. The protocols are devised by the physician/ radiologist who has previously indicated the amount of contrast media required for the particular test.
Formulary Pg. 28			
June 2011			
Ipilimumab Injection	Yervoy	<i>Antineoplastic Agents: Monoclonal Antibodies.</i> Indicated for the treatment of unresectable or metastatic melanoma.	9/19/11 CTP holder May NOT prescribe.
Formulary Pg. 28			
July 2011			
Linagliptin	Tradjenta	<i>Endocrine & Metabolic Agents: Dipeptidyl Peptidase-4 Inhibitor.</i> Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.	9/19/11 CTP holder may prescribe.
Formulary Pg. 9			
Vandetanib	Vandetanib	<i>Antineoplastic Agents: Tyrosine Kinase Inhibitor.</i> Indicated for the treatment of symptomatic or progressive medullary thyroid cancer.	9/19/11 CTP holder May NOT prescribe.
Formulary Pg. 26			

Formulary Pg. 26		prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.	
------------------	--	------------------------------------------------------------------------------------------------	--

New Drugs Indications/ Warnings September 2011

(New Drug Indications/ Black Box Warnings: FDA)

Generic Name	Trade Name	Indication(s)	CPG Action/Date
May 2011			
Glycopyrrolate Formulary Pg. 20	Cuvposa	<i>Gastrointestinal Agents: Gastrointestinal Anticholinergics/Antispasmodics.</i> New indication for reducing chronic, severe drooling in children 3 to 16 years of age with neurologic conditions associated with problem drooling.	Current: CTP holder May prescribe. 9/19/11 No Change.
June 2011			
Levonorgestrel-Releasing-Intrauterine Device Formulary Pg. 8	Mirena	<i>Endocrine & Metabolic Agents: Sex Hormones: Contraceptive Hormones.</i> New indication for the treatment of heavy menstrual bleeding.	Current: CTP holder May prescribe. 9/19/11 No Change.
July 2011			
Cinacalcet Formulary Pg. 10	Sensipar	<i>Endocrine & Metabolic Agents: Calcium Receptor Agonists.</i> New indication for the treatment of severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy.	Current: Physician Initiated/Physician Consult 9/19/11 No Change.
August 2011			
Fibrin Sealant (Human)	Tisseel, TachoSil	<i>Dermatological Agents: Fibrin Sealants.</i> TachoSil is indicated as an adjunct agent to hemostasis for use in cardiovascular surgery when control of bleeding by standard surgical techniques is ineffective or impractical. Tisseel is indicated as an adjunct to hemostasis in surgeries involving	Current: CTP holder May prescribe. 9/19/11 No Change.

<p>Formulary Pg. 24</p>		<p>cardiopulmonary bypass and treatment of splenic injuries when control of bleeding by conventional surgical techniques is ineffective or impractical and as an adjunct to prevent leakage from colonic anastomoses following reversal of temporary colostomies.</p>	
<p>Toremifene Citrate Oral</p> <p>Formulary Pg. 27</p>	<p>Fareston</p>	<p><i>Antineoplastic Agents:</i> <i>Hormones:</i> <i>Antiestrogens.</i> New black box warning for prolongation of the QT interval.</p>	<p>Current: CTP holder May NOT prescribe.</p> <p>Physician Initiated/Physician Consult for prescribers who have and maintain a standard care arrangement with a collaborating hematologist/oncologist.</p> <p>9/19/11 No Change.</p>
<p>Rituximab</p> <p>Formulary Pg. 28</p>	<p>Rituxan</p>	<p><i>Antineoplastic Agents:</i> <i>Monoclonal Antibodies.</i> New indication for use in combination with glucocorticoids for the treatment of adult patients with microscopic polyangiitis and treatment of adult patients with Wegener granulomatosis.</p>	<p>Current: CTP holder May NOT prescribe.</p> <p>9/19/11 No Change.</p>

Formulary Revision Request September 2011
(Original New Drug Applications: FDA)

Generic Name	Trade Name	Indication(s)	CPG Action/Date
Shannon Cherney, CNP			
<p>Botulinum Toxin Type A</p> <p>Formulary Pg. 20</p>	<p>Botox</p>	<p><i>Central Nervous System Agents: Botulinum Toxins.</i></p> <p>Indicated for the treatment of, severe primary axillary hyperhidrosis, cervical dystonia in adult patients, adult patients with chronic migraine, the appearance of moderate to severe glabellar lines, strabismus and blepharospasm associated with dystonia, and upper limb spasticity in adults.</p> <p>Requesting Physician Initiated/ Physician Consult.</p>	<p>Current: CTP holder May NOT prescribe.</p> <p>Physician Initiated/ Physician Consult for spasticity and cervical dystonia, must be addressed specifically in the standard care arrangement</p> <p>9/19/11 Physician Initiated/ Physician Consult for spasticity, cervical dystonia, and chronic migraine in related specialty clinic, must be addressed specifically in the standard care arrangement.</p>
Cathy Dobrowski, MSN, ANP-BC			
<p>Botulinum Toxin Type A</p>	<p>Botox</p>	<p><i>Central Nervous System Agents: Botulinum Toxins.</i></p> <p>Indicated for the treatment of, severe primary axillary hyperhidrosis, cervical dystonia in adult patients, adult patients with chronic migraine, the appearance of moderate to severe glabellar lines, strabismus and blepharospasm</p>	<p>Current: CTP holder May NOT prescribe.</p> <p>Physician Initiated/ Physician Consult for spasticity and cervical dystonia, must be addressed specifically in the standard care arrangement.</p>

**Review of Prescribing Designations PI/PC and CTP Holder
May NOT Prescribe
Cardiovascular Agents
(September 2011)**

Drug Category/Drug Name	Indications(s)	Current Prescribing Designation	CPG Action/Date
Inotropic Agents			
Inotropic Agents IV Formulary Pg. 11	<i>Inotropic Agents.</i> Indicated for the treatment of heart failure and atrial fibrillation.	CTP holder May NOT prescribe. * see Footnote 1 Physician Consult for non-acute care CTP holder in institutional setting per institutional protocol and as stated in the standard care arrangement.	9/19/11 No Change.
Antiarrhythmic Agents			
Antiarrhythmic Agents IV Formulary Pg. 11	<i>Antiarrhythmic Agents.</i>	Physician Consult for non-acute care CTP holders in an institutional setting per institution protocol for monitored patient care units and as stated in the standard care arrangement. CTP holder May NOT prescribe for CTP holder who is not an Acute Care NP/CNS, or Neonatal NP.	9/19/11 No Change.

Calcium Channel Blocking Agents			
<p>Calcium Channel Blocking Agents IV</p> <p>Formulary Pg. 12</p>	<p><i>Calcium Channel Blocking Agents.</i> Indicated for treatment of spontaneous coronary artery spasm, chronic stable angina, unstable angina at rest, hypertension, improvement of neurological outcome in patients with subarachnoid hemorrhage, rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm, prophylaxis of PSVT, and temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter.</p>	<p>CTP holder May NOT prescribe.</p> <p>Acute Care CTP holders only may prescribe.</p> <p>Physician Consult for non-acute care CTP holder per institution protocol in monitored units and as stated in the standard care arrangement.</p> <p>* see Footnote 1</p>	<p>9/19/11 No Change.</p>
<p>Clevidipine Butyrate Injection (Cleviprex)</p> <p>Formulary pg. 12</p>	<p><i>Calcium Channel Blocking Agents.</i> Indicated for the reductions of blood pressure when oral therapy is not feasible or desirable.</p>	<p>CTP holder May NOT prescribe.</p> <p>Acute care CTP holders only may prescribe.</p>	<p>9/19/11 No Change.</p>
<p>Nimodipine (Nimodipine, Nimotop)</p> <p>Formulary Pg. 12</p>	<p><i>Calcium Channel Blocking Agents.</i> Indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage.</p>	<p>Physician Initiated/ Physician Consult</p>	<p>9/19/11 No Change.</p>

Vasodilators			
<p>Nitrates IV</p> <p>Formulary Pg. 12</p>	<p><i>Vasodilators: Nitrates.</i> Indicated for rapid relief or angina pectoris, prevention of angina pectoris caused by CAD, treatment of perioperative hypertension, and for control of congestive heart failure in the setting of acute myocardial infarction.</p>	<p>CTP holder May NOT prescribe.</p> <p>* see Footnote 1</p>	<p>9/19/11 No Change.</p>
<p>Endothelin Receptor Antagonist</p> <p>Formulary Pg. 12</p>	<p><i>Vasodilators: Endothelin Receptor Antagonist.</i></p>	<p>Physician Initiated/ Physician Consult</p>	<p>9/19/11 No Change.</p>
<p>Peripheral Vasodilators IV</p> <p>Formulary Pg. 12</p>	<p><i>Vasodilators: Peripheral Vasodilators.</i></p>	<p>CTP holder who is not an Acute Care NP/CNS, or Neonatal NP May Not Prescribe.</p>	<p>9/19/11 No Change.</p>
<p>Epoprostenol Sodium Injection (Flolan)</p> <p>Formulary Pg. 12</p>	<p><i>Vasodilators: Peripheral Vasodilators.</i> Indicated for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.</p>	<p>Physician Initiated/ Physician Consult for CTP holder within specialty clinic.</p>	<p>9/19/11 No Change.</p>

<p>Treprostinil Sodium (Remodulin)</p> <p>Formulary Pg. 12</p>	<p><i>Vasodilators: Peripheral Vasodilators.</i> Indicated for the treatment of pulmonary arterial hypertension in patients with New York Heart Association (NYAH) class II to IV symptoms to diminish symptoms associated with exercise, and to diminish the rate of clinical deterioration in patients requiring transition from epoprostenol.</p>	<p>Physician Initiated/ Physician Consult for CTP holder within specialty clinic.</p>	<p>9/19/11 No Change.</p>
<p>Hydralazine HCL IV (Hydralazine, Apresoline)</p> <p>Formulary Pg. 12</p>	<p><i>Vasodilators: Peripheral Vasodilators.</i> Indicated for severe essential hypertension when the drug cannot be given orally or when the need to lower blood pressure is urgent.</p>	<p>CTP holder May NOT prescribe.</p> <p>Acute Care CTP holders only may prescribe.</p> <p>Physician Consult non- acute care CTP holder per institution protocol in monitored units and as stated in the standard care arrangement.</p> <p>* see Footnote 1</p>	<p>9/19/11 No Change.</p>
<p>Vasodilator Combinations</p> <p>Formulary Pg. 13</p>	<p><i>Vasodilators: Vasodilator Combinations.</i></p>	<p>Physician Initiated/ Physician Consult</p>	<p>9/19/11 No Change.</p>

Antiadrenergics/ Sympatholytics			
<p>Beta-blockers IV</p> <p>Formulary Pg. 12</p>	<p><i>Antiadrenergics/ Sympatholytics: Beta-Adrenergic Blocking Agents.</i> Indicated for treatment of hypertension, long-term management of angina pectoris, managing exertional or other stress induced angina, palpitations, and syncope, cardiac arrhythmias, intraoperative and postoperative tachycardia and hypertension, and maintenance of sinus rhythm in patients with atrial fibrillation/atrial flutter.</p>	<p>CTP holder May NOT prescribe.</p> <p>Acute Care CTP holders only may prescribe.</p> <p>Physician Consult non-acute care CTP holder per institution protocol in monitored units and as stated in the standard care arrangement.</p> <p>*see Footnote 1</p>	<p>9/19/11 No Change.</p>
<p>Alpha/Beta Adrenergics IV</p> <p>Formulary Pg. 12</p>	<p><i>Antiadrenergic/ Sympatholytics: Alpha/Beta- Adrenergic Blocking Agents.</i> Indicated for</p>	<p>CTP holder May not prescribe.</p> <p>*see Footnote 1</p>	<p>9/19/11 No Change.</p>
Renin Angiotensin System Antagonists			
<p>Renin Angiotensin System Antagonists IV</p> <p>Formulary Pg. 13</p>	<p><i>Renin Angiotensin System Antagonists.</i></p>	<p>CTP holder May NOT prescribe.</p> <p>*see Footnote 1</p>	<p>9/19/11 No Change.</p>
Agents for Pheochromocytoma			
<p>Agents for Pheochromocytoma</p> <p>Formulary Pg. 13</p>	<p><i>Agents for Pheochromocytoma</i></p>	<p>CTP holder May NOT prescribe.</p>	<p>9/19/11 No Change.</p>

Agents for Hypertensive Emergencies			
<p>Nitroprusside Sodium (Sodium Nitroprusside, Nitropress)</p> <p>Formulary Pg. 13</p>	<p><i>Agents for Hypertensive Emergencies.</i> Indicated for the immediate reduction of blood pressure of patients in hypertensive crises, production of controlled hypotension in order to reduce bleeding during surgery, and for use in acute congestive heart failure.</p>	<p>CTP holder May NOT prescribe.</p> <p>*see Footnote 1</p>	<p>9/19/11 No Change.</p>
<p>Diazoxide, Parenteral (Hyperstat IV)</p> <p>Formulary Pg. 13</p>	<p><i>Agents for Hypertensive Emergencies.</i> Indicated for emergency reduction of blood pressure in severe malignant and nonmalignant hypertension.</p>	<p>CTP holder May NOT prescribe.</p> <p>*see Footnote I</p>	<p>9/19/11 No Change.</p>
<p>Fenoldopam Mesylate (Corloпам)</p> <p>Formulary Pg. 13</p>	<p><i>Agents for Hypertensive Emergencies.</i> Indicated for the in-hospital short term management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated.</p>	<p>CTP holder May NOT prescribe.</p> <p>*see Footnote 1</p>	<p>9/19/11 No Change.</p>

<p>Trimethaphan Camsylate (Arfonad)</p> <p>Formulary Pg. 13</p>	<p><i>Agents for Hypertensive Emergencies.</i> Indicated for the production of controlled hypotension during surgery, for the short-term acute control of blood pressure in hypertensive emergencies, in the emergency treatment of pulmonary edema in patients with pulmonary hypertension associated with systemic hypertension.</p>	<p>CTP holder May NOT prescribe.</p> <p>*see Footnote 1</p>	<p>9/19/11 No Change.</p>
<p>Antihyperlipidemic Agents</p>			
<p>HMG-CoA Reductase Inhibitors</p> <p>Formulary Pg. 13</p>	<p><i>Antihyperlipidemic Agents: HMG-CoA Reductase Inhibitors.</i> Indicated for primary prevention of cardiovascular disease in patients with multiple risk factors, reducing angina risk, reducing MI risk, reducing stroke risk, reducing risk for revascularization procedures, reduce risk of CV mortality, slow progression of coronary atherosclerosis, reduce risk of total mortality by reducing coronary death, and hypercholesterolemia.</p>	<p>Physician Initiated/ Physician Consult for pediatric dosing.</p>	<p>9/19/11 No Change.</p>

Vasopressors Used in Shock			
Vasopressors Used in Shock Formulary Pg. 13	<i>Vasopressors Used in Shock.</i> Indicated to treat hypoperfusion in shock, maintain blood pressure in cardiogenic or advanced shock, and to improve cardiac output.	CTP holder May NOT prescribe. *see Footnote 1	9/19/11 No Change.
Potassium Removing Resins			
Potassium Removing Resins Formulary Pg. 13	<i>Potassium Removing Resins.</i> Indicated for the treatment of hyperkalemia.	Physician Initiated/ Physician Consult	9/19/11 CTP holder may prescribe.
Cardioplegic Solutions			
Cardioplegic Solutions. Formulary Pg. 13	<i>Cardioplegic Solutions.</i> Indicated for inducing cardiac arrest during open-heart surgery.	CTP holder May NOT prescribe.	9/19/11 No Change.
Agents for Patent Ductus Arteriosus			
Ibuprofen Lysine (NeoProfen) Formulary Pg. 13	<i>Agents for Patent Ductus Arteriosus.</i> Indicated to close a clinically significant PDA in premature infants who are no more than 32 weeks gestational age when usual medical management is ineffective.	Physician Initiated/ Physician Consult	9/19/11 Neonatal NP only may prescribe.
Indomethacin (Indocin I.V.) Formulary Pg. 13	<i>Agents for Patent Ductus Arteriosus.</i> Indicated for closure of hemodynamically significant PDA in premature infants if, after 48 hours, usual medical management is ineffective.	Physician Initiated/ Physician Consult	9/19/11 No Change.

Sclerosing Agents			
Sclerosing Agents Formulary Pg. 13	<i>Sclerosing Agents.</i> Indicated for treatment of small, uncomplicated varicose veins of the lower extremities.	CTP holder May NOT prescribe.	9/19/11 No Change.
Miscellaneous Antianginal Agents			
Ranolazine (Ranexa) Formulary Pg. 13	<i>Miscellaneous Antianginal Agents.</i> Indicated for the treatment of chronic angina.	CTP holder may prescribe ADULT Acute Care ONLY Physician Initiated/ Physician Consult all other CTP holders.	9/19/11 No Change.

**Review of Prescribing Designations PI/PC and CTP Holder
May NOT Prescribe
Respiratory Agents
(September 2011)**

Drug Category/Drug Name	Indications(s)	Current Prescribing Designation	CPG Action/Date
Monoclonal Antibodies			
Omalizumab (Xolair) Formulary Pg. 14	<i>Monoclonal Antibodies.</i> Indicated to decrease the incidence of asthma exacerbations for adults and adolescents 12 years of age and older with moderate to severe persistent asthma.	Physician Initiated/ Physician Consult.	9/19/11 No Change.
Respiratory Enzymes			
Respiratory Enzymes Formulary Pg. 14	<i>Respiratory Enzymes.</i> Indicated for chronic augmentation therapy in patients having congenital deficiency of alpha1-PI with clinically evident emphysema.	CTP holder may prescribe for Neonatal Nurse Practitioner only. Physician Initiated/ Physician Consult all other CTP holders.	9/19/11 No Change.
Lung Surfactants			
Lung Surfactants Formulary Pg. 14	<i>Lung Surfactants.</i> Indicated for prevent and treatment of RDA (hyaline membrane disease) in premature infants.	CTP holder may prescribe Neonatal Nurse Practitioner only.	9/19/11 No Change.

**Review of Prescribing Designations PI/PC and CTP Holder
May NOT Prescribe
Central Nervous System Agents
(September 2011)**

Drug Category/Drug Name	Indications(s)	Current Prescribing Designation	CPG Action/Date
CNS Stimulants			
<p>Analeptics</p> <p align="center">Caffeine</p> <p>Formulary Pg. 15</p>	<p><i>Central Nervous System Agents: CNS Stimulants: Analeptics.</i> Indicated as an aid in staying awake and restoring mental alertness, as an adjunct in analgesic formulations, for the short-term treatment of apnea in premature infants, and in conjunction with supportive measures to treat respiratory depression associated with overdosage with CNS depressants.</p>	<p>Physician Initiated/ Physician Consult</p>	<p>9/19/11 PO- CTP holder may prescribe.</p> <p>9/19/11 IV- No Change.</p>
<p>Doxapram HCL (Doxapram, Dopram)</p> <p>Formulary Pg. 15</p>	<p><i>Central Nervous System Agents: CNS Stimulants: Analeptics.</i> Indicated for use to stimulate respiration in patients with drug-induced post-anesthesia respiratory depression or apnea, to stimulate respiration, hasten arousal, and encourage return of laryngo-pharyngeal reflexes in patients with mild to moderate respiratory and CNS depression, and as a temporary measure in hospitalized patients with acute respiratory insufficiency</p>	<p>CTP holder May NOT prescribe.</p>	<p>9/19/11 No Change.</p>

Miscellaneous Analgesics			
Ziconotide (Prialt) Formulary Pg. 16	<i>Central Nervous Agents: Miscellaneous Agents.</i> Indicated for the management of severe chronic pain in patients for whom intrathecal therapy is warranted.	CTP holder May NOT prescribe.	9/19/11 No Change.
Antiemetic/Antivertigo Agents			
Aprepitant (Emend) Formulary Pg. 16	<i>Miscellaneous.</i> Indicated for prevention of nausea/vomiting associated with moderate or highly emetogenic cancer chemotherapy and prevention of postoperative nausea/vomiting.	CTP holder may prescribe for prescribers who have a standard care arrangement with a collaborating Hematologist/Oncologist. CTP may NOT prescribe for CTP holders who do not have a standard care arrangement with a collaborating Hematologist/Oncologist.	9/19/11 No Change.
Antianxiety Agents			
Meprobamate (Equanil, Miltown) Formulary Pg. 17	<i>Antianxiety Agents.</i> Indicated for management of anxiety disorders or short-term relief of the symptoms of anxiety.	CTP holder May NOT prescribe.	9/19/11 No Change.
Antidepressants			
Amoxapine (Amoxapine) Formulary Pg. 17	<i>Antidepressants.</i> Indicated for relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions.	Physician Initiated/ Physician Consult	9/19/11 CTP holder may prescribe.
Nefazodone (Nefazodone HCL) Formulary Pg. 17	<i>Antidepressants.</i> Indicated for the treatment of depression.	Physician Initiated/ Physician Consult	9/19/11 No Change.

MAO Inhibitors Formulary Pg. 17	<i>Antidepressants: Monoamine Oxidase Inhibitors.</i> Indicated for use in patients with atypical depression and in some patients unresponsive to other antidepressive therapy.	Physician Initiated/ Physician consult	9/19/11 No Change.
Antipsychotic Agents			
Thioridazine Hydrochloride (Thioridazine HCL) Formulary Pg. 17	<i>Antipsychotic Agents.</i> Indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs.	Physician Initiated/ Physician Consult	9/19/11 No Change.
Clozapine (Clozapine, FazaClo) Formulary Pg. 17	<i>Antipsychotic Agents.</i> Indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder.	Physician Initiated/ Physician Consult	9/19/11 No Change.
Pimozide (Orap) Formulary Pg. 17	<i>Antipsychotic Agents.</i> Indicated for suppression of motor and phonic tics in patients with Tourette disorder who have failed to respond to standard treatment.	Physician Initiated/ Physician Consult	9/19/11 No Change.
Lithium (Lithium Carbonate, Eskalith) Formulary Pg. 17	<i>Antipsychotic Agents.</i> Indicated for the treatment of manic episodes of manic-depressive illness.	CTP holder may prescribe for psych CTP holder. Physician Initiated/ Physician Consult for CTP holder other than psych. Initial 30-day review.	9/19/11 No Change.
NMDA Receptor Antagonists			
Memantine Hydrochloride (Namenda) Formulary Pg. 17	<i>NMDA Receptor Antagonists.</i> Indicated for the treatment of moderate to severe dementia of the Alzheimer type.	Physician Initiated/ Physician Consult	9/19/11 No Change.

Miscellaneous Psychotherapeutic Agents			
<p>Chlordiazepoxide and Amitriptyline (Limbitrol)</p> <p>Formulary Pg. 17</p>	<p><i>Miscellaneous Psychotherapeutic Agents.</i> Indicated for the treatment of moderate to severe depression associated with moderate to severe anxiety.</p>	<p>Physician Initiated/ Physician Consult</p>	<p>9/19/11 No Change.</p>
<p>Perphenazine and Amitriptyline (Etrafon, Triavil,</p> <p>Formulary Pg. 17</p>	<p><i>Miscellaneous Psychotherapeutic Agents.</i> Indicated for the treatment of moderate to severe anxiety or agitation and depressed mood.</p>	<p>Physician Initiated/ Physician Consult</p>	<p>9/19/11 No Change.</p>
<p>Ergoloid Mesylates (Gerimal, Hydergine)</p> <p>Formulary Pg. 17</p>	<p><i>Miscellaneous Psychotherapeutic Agents.</i> Indicated for individuals over age 60 who manifest signs and symptoms of an idiopathic decline in mental capacity.</p>	<p>Physician Initiated/ Physician Consult</p>	<p>9/19/11 No Change.</p>
<p>Sodium Oxybate (Xyrem)</p> <p>Formulary Pg. 17</p>	<p><i>Miscellaneous Psychotherapeutic Agents.</i> Indicated for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy.</p>	<p>Physician Initiated/ Physician Consult</p>	<p>9/19/11 No Change.</p>
<p>Olanzapine/ Fluoxetine (Symbyax)</p> <p>Formulary Pg. 17</p>	<p><i>Miscellaneous Psychotherapeutic Agents.</i> Indicated for the acute treatment of depressive episodes associated with bipolar I disorder in adults and for acute treatment of treatment-resistant depression in adults who do not respond to 2 separate trials of different antidepressants during the current episode.</p>	<p>Physician Initiated/ Physician Consult</p>	<p>9/19/11 No Change.</p>

<p>Atomoxetine (Strattera)</p> <p>Formulary Pg. 18</p>	<p><i>Miscellaneous Psychotherapeutic Agents.</i> Indicated for the treatment of ADHD.</p>	<p>CTP holder may prescribe for psych CTP holder. Initial 60-day review.</p> <p>Physician Initiated/ Physician Consult for CTP holder other than psych. Initial 60 day review.</p>	<p>9/19/11 No Change.</p>
<p>Sedatives and Hypnotics, nonbarbiturate</p>			
<p>Chloral Hydrate (Somnote, Aquachloral Supprettes)</p> <p>Formulary Pg. 18</p>	<p><i>Sedatives and Hypnotics, nonbarbiturate.</i> Indicated for preoperative sedation to lessen anxiety and induce sleep, postoperative care and control of pain as an adjunct to opiates and analgesics, and for preventing or suppressing alcohol withdrawal symptoms (rectal).</p>	<p>CTP holder May NOT prescribe.</p>	<p>9/19/11 Physician Initiated/ Physician Consult</p>
<p>Paraldehyde (Paral)</p> <p>Formulary Pg. 18</p>	<p><i>Sedatives and Hypnotics, nonbarbiturate.</i> Indicated to quiet patients and produce sleep in delirium tremens and in other psychiatric states characterized by excitement.</p>	<p>CTP holder May NOT prescribe.</p>	<p>9/19/11 No Change.</p>
<p>Dexmedetomidine (Precedex)</p> <p>Formulary Pg. 18</p>	<p><i>Sedatives and Hypnotics, nonbarbiturate.</i> Indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care unit setting and for sedation of nonintubated patients prior to and/or during surgical and other procedures.</p>	<p>CTP holder May NOT prescribe.</p>	<p>9/19/11 No Change.</p>

Sedatives and Hypnotics, Barbiturates			
Intermediate-Acting Formulary Pg. 18	<i>Sedatives and Hypnotics, Barbiturates.</i>	CTP holder May NOT prescribe.	9/19/11 No Change.
Short- Acting Formulary Pg. 18	<i>Sedatives and Hypnotics, Barbiturates.</i>	CTP holder May NOT prescribe.	9/19/11 No Change.
Oral Combinations Formulary Pg. 18	<i>Sedatives and Hypnotics, Barbiturates.</i>	CTP holder May NOT prescribe.	9/19/11 No Change.
General Anesthetics			
General Anesthetics Formulary Pg. 18	<i>General Anesthetics.</i>	CTP holder May NOT prescribe.	9/19/11 No Change.
Anticonvulsants			
Vigabatrin (Sabril) Formulary Pg. 19	<i>Anticonvulsants.</i> Indicated for infants and children with infantile spasms for whom the potential benefits outweigh the potential risk of vision loss and as an adjunctive therapy for adults with refractory complex partial seizures.	CTP holder May NOT prescribe.	9/19/11 No Change.
Muscle Relaxants – Adjuncts to Anesthesia			
Muscle Relaxants – Adjuncts to Anesthesia Formulary Pg. 19	<i>Muscle Relaxants- Adjuncts to Anesthesia.</i>	CTP holder May NOT prescribe.	9/19/11 No Change.
Antiparkinson Agents			
Selegiline Hydrochloride Transdermal (EMSAM) Formulary Pg. 19	<i>Antiparkinson Agents.</i> Indicated for the treatment of major depressive disorder.	Physician Initiated/ Physician Consult	9/19/11 No Change.

Adenosine Phosphate			
Adenosine Phosphate Formulary Pg. 19	<i>Adenosine Phosphate.</i> Indicated for symptomatic relief of complications with stasis dermatitis (varicose veins).	Physician Initiated/ Physician Consult	9/19/11 No Change.
Cholinergic Muscle Stimulants			
Cholinergic Muscle Stimulants Formulary Pg. 19	<i>Cholinergic Muscle Stimulants.</i>	Physician Initiated/ Physician Consult	9/19/11 No Change.
Riluzole			
Riluzole (Rilutek) Formulary Pg. 19	<i>Riluzole.</i> Indicated for the treatment of patients with amyotrophic lateral sclerosis. Riluzole extends survival and/or time to tracheostomy.	Physician Initiated/ Physician Consult	9/19/11 No Change.
Physical Adjuncts			
Hyaluronic Acid Derivatives (Euflexxa, Hyalgan, Supartz, Orthovisc, Synvisc) Formulary Pg. 19	<i>Physical Adjuncts.</i> Indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics.	Physician Initiated/ Physician Consult	9/19/11 No Change.
Hyaluronic Acid Derivatives Injection (Hylaform, Perlane, Restylane, Juvederm, Bionect, Hylira) Formulary Pg. 19	<i>Physical Adjuncts.</i> Indicated for mid to deep dermal implantation for the correction of moderate to severe facial wrinkles and folds.	Physician Initiated/ Physician Consult	9/19/11 No Change.
Calcium Hydroxylapatite Implant (Radiesse) Formulary Pg. 19	<i>Physical Adjuncts.</i> For the restoration and/or correction of the signs of facial fat loss in persons with HIV and for subdermal implantation for the correction of moderate to severe facial wrinkles and folds.	CTP holder May NOT prescribe.	9/19/11 No Change.

<p>Poly-L-Lactic Acid (Sculptra)</p> <p>Formulary Pg. 19</p>	<p><i>Physical Adjuncts.</i> For restoration and/or correction of the signs of facial fat loss in people with HIV.</p>	<p>CTP holder May NOT prescribe.</p>	<p>9/19/11 No Change.</p>
<p>Potassium Channel Blocker</p>			
<p>Dalfampridine (Ampyra)</p> <p>Formulary Pg. 19</p>	<p><i>Potassium Channel Blocker.</i> Indicated to improve walking in patients with multiple sclerosis.</p>	<p>Physician Initiated/ Physician Consult</p>	<p>9/19/11 No Change.</p>
<p>Botulinum Toxins</p>			
<p>Botulinum Toxins Type A (Botox, Dysport, Xeomin)</p> <p>Formulary Pg. 20</p>	<p><i>Botulinum Toxins: Botulinum Toxins Type A.</i> Indicated for the treatment of severe primary axillary hyperhidrosis, treatment of cervical dystonia, prophylaxis of headaches in adults with chronic migraine, for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults 65 years of age and younger, treatment of strabismus and blepharospasm associated with dystonia, and treatment of upper limb spasticity in adults.</p>	<p>CTP holder May NOT prescribe.</p> <p>Physician Initiated/ Physician Consult for spasticity and cervical dystonia, must be addressed specifically in the standard care arrangement.</p>	<p>9/19/11 Physician Initiated/ Physician Consult for spasticity, cervical dystonia, and chronic migraine in related specialty clinic, must be addressed specifically in the standard care arrangement.</p>
<p>Rimabotulinumtoxin B (Myobloc)</p> <p>Formulary Pg. 20</p>	<p><i>Botulinum Toxins: Botulinum Toxin Type B.</i> Indicated for the treatment of adults with cervical dystonia.</p>	<p>CTP holder May NOT prescribe.</p> <p>Physician Initiated/ Physician Consult for spasticity and cervical dystonia, must be addressed specifically in the standard care arrangement.</p>	<p>9/19/11 No Change.</p>

Tetrabenazine			
Tetrabenazine (Xenazine) Formulary Pg. 20	<i>Tetrabenazine.</i> Indicated for the treatment of chorea associated with Huntington disease.	CTP holder May NOT prescribe.	9/19/11 No Change.